$TRIL Having established preliminary efficacy, the next objective is to identify the recommended phase II dose of TTI-621 in part 4 of this ongoing study. Once the dose is determined, the therapeutic potential of TTI-621 as monotherapy and combined with other immunooncology agents will be explored further in future studies. clincancerres.aacrjournals....
2
5
5 Likes